ADMA: What This Molecule Tells You About Your Blood Vessels

ADMA: A plain-language definition of the molecule

ADMA (asymmetric dimethylarginine) is a molecule your body makes when proteins containing methylated arginine residues are broken down. It circulates in the blood and acts as an endogenous inhibitor of endothelial nitric oxide synthase (eNOS), competing with L-arginine — the normal substrate for nitric oxide production. More ADMA typically means less nitric oxide, which can push blood vessels toward constriction and impaired endothelial function. ADMA is produced via protein arginine methyltransferases (PRMTs) and cleared primarily by the enzyme dimethylarginine dimethylaminohydrolase (DDAH) and the kidneys.

How ADMA blocks nitric oxide production

Your cells methylate arginine residues on proteins as part of normal regulation. When those proteins are recycled, ADMA is released into circulation. The liver and kidneys, via DDAH, break it down. Oxidative stress and inflammation can blunt DDAH activity, so ADMA builds up even when kidney clearance is intact — this is the DDAH-inhibition confounder. Kidney impairment reduces clearance independently, pushing levels higher through a separate mechanism. That's why ADMA tends to track with conditions that strain the endothelium, from hypertension to diabetes to chronic kidney disease.

It's important to note that ADMA does not measure nitric oxide directly — it measures a key inhibitor of its production. Multiple cohort studies link higher ADMA to increased cardiovascular events and mortality, particularly in chronic kidney disease and in people with established vascular risk, though causality is not proven. One number is a snapshot; the trend is the story.

Reading your ADMA result against the range

ADMA is typically reported in micromoles per liter (µmol/L), but reference ranges vary by lab and method. Some labs use mass spectrometry (LC-MS/MS), others immunoassays — methods are not interchangeable, and absolute values can differ between them. Age, kidney function, and cardiometabolic status also shift the distribution. Lab reference intervals reflect where most people fall, not a guarantee of vascular health. "Optimal" means levels associated with better endothelial function and lower risk in studies, not a universal cut line.

Normal

A commonly cited reference range is approximately 0.4–0.9 µmol/L, though this varies by assay method and laboratory. Results within this range, in the context of normal kidney function and low inflammatory markers, are generally consistent with adequate nitric oxide bioavailability. The optimal end of this range — rather than simply the population average — is associated with more favorable endothelial function in research cohorts. Treat your result as one input alongside blood pressure, renal markers, and metabolic status, not as a standalone diagnosis.

When levels run high

Elevated ADMA may indicate reduced nitric oxide availability and warrants evaluation in context. Three patterns are worth recognizing: elevated ADMA with a reduced eGFR suggests clearance issues as the primary driver; elevated ADMA with high hs-CRP points toward inflammatory pressure on DDAH activity; and elevated ADMA with insulin resistance and central adiposity hints at endothelial stress from metabolic load. Aging tends to nudge ADMA upward. Smoking and untreated sleep apnea can do the same via oxidative pathways. Confirm persistence on repeat testing, align the result with related markers, and look for a coherent story rather than reacting to a single outlier.

When levels run low

Lower ADMA can reflect healthier nitric oxide signaling or robust DDAH activity, and may appear alongside strong cardiorespiratory fitness, well-controlled blood pressure, and low inflammatory markers. However, lower is not automatically better if the value is discordant with your clinical picture. Lab variation, sample timing, hydration, and assay method can all nudge results. If a result looks surprisingly low or shifts abruptly, recheck with the same lab and method before drawing conclusions.

Factors that move your ADMA number

Several modifiable and non-modifiable factors influence ADMA levels through the two primary mechanisms: DDAH activity and kidney clearance.

• Kidney function: Reduced eGFR is one of the primary drivers of ADMA accumulation. Impaired clearance raises circulating levels independently of production rate.
• Oxidative stress and DDAH inhibition: Oxidative stress blunts DDAH activity, allowing ADMA to build up even when kidney function is intact. Conditions that increase oxidative load — including smoking, sleep apnea, and poor glycemic control — can push ADMA upward through this pathway.
• Inflammation: Elevated inflammatory markers such as hs-CRP track with DDAH inhibition and endothelial stress, contributing to higher ADMA independent of kidney function.
• Insulin resistance and central adiposity: Metabolic strain from insulin resistance is associated with elevated ADMA, likely through increased oxidative stress and endothelial dysfunction.
• Sleep apnea: Untreated sleep apnea is linked with higher ADMA via oxidative and sympathetic pathways. Fragmented or insufficient sleep raises inflammatory mediators that inhibit DDAH.
• Smoking: Smoking elevates ADMA through oxidative mechanisms.
• Dietary patterns: Diets rich in nitrate-containing vegetables (beets, arugula, spinach) support a parallel nitrate–nitrite–NO pathway. Arginine- and citrulline-containing foods (legumes, nuts, seeds) increase substrate availability; the L-arginine to ADMA ratio is the functional confounder of note — a higher ratio generally signals better nitric oxide potential. Steady glycemic control reduces oxidative stress on DDAH.
• Exercise: Sustained aerobic and resistance training programs are associated with modest reductions in ADMA, particularly when paired with cardiometabolic improvements. Very intense single sessions may transiently increase oxidative stress and nudge ADMA upward before longer-term adaptation occurs.
• Pregnancy and preeclampsia: Pregnancy physiology alters nitric oxide signaling and can shift ADMA; preeclampsia has been associated with higher levels in studies.
• Homocysteine and methylation status: Hyperhomocysteinemia is a convergent driver of DDAH inhibition; folate and B-vitamin status influence one-carbon metabolism and track with endothelial function in several studies.

Markers that read ADMA in context

ADMA is most informative when interpreted alongside markers that distinguish its two primary drivers — DDAH inhibition and kidney clearance — and that capture the broader endothelial environment.

• SDMA — SDMA is structurally similar to ADMA but does not inhibit eNOS. If SDMA is high alongside ADMA, kidney clearance is likely the primary driver; if SDMA is normal and ADMA is elevated, oxidative stress and DDAH inhibition are more probable.
• eGFR — Reduced eGFR is a primary mechanism driving ADMA accumulation; separating clearance-driven from inflammation-driven elevation requires the kidney lens.
• hs-CRP — hs-CRP flags the inflammation that can inhibit DDAH activity and push ADMA upward independent of kidney function. The ADMA + hs-CRP + eGFR triple is the key discordance cluster.
• Homocysteine — Hyperhomocysteinemia is a convergent driver of DDAH inhibition and endothelial dysfunction; pairing these markers clarifies whether elevated ADMA has a methyl-metabolism component.
• Creatinine — baseline creatinine provides a rapid first-pass estimate of kidney function before formal eGFR calculation; useful when eGFR is not on the panel.

A realistic retest window for ADMA

ADMA is a responsive marker. Meaningful shifts can occur within 4–12 weeks following lifestyle interventions, improvements in cardiometabolic status, or changes in arginine availability. Statin therapy or significant dietary changes may produce a measurable ADMA shift by 8–12 weeks, though individual responses vary.

Because ADMA assays are more sensitive to sample handling than most standard markers, standardizing draw conditions is essential for reliable trend data. Hemolysis and delayed sample processing can skew results. Fasting state and draw timing should be kept consistent between tests. Most importantly: use the same lab and the same assay method — LC-MS/MS and immunoassay values are not interchangeable, and switching methods between draws makes trend interpretation unreliable.

When ADMA findings warrant follow-up with a provider

A persistently elevated ADMA — particularly when it converges with reduced eGFR, elevated hs-CRP, or markers of insulin resistance — warrants discussion with a clinician. This pattern suggests a combination of impaired clearance and active endothelial stress that goes beyond what a single biomarker can characterize. Similarly, an unexpectedly low or abruptly shifted result should be rechecked before acting on it, given the assay's sensitivity to sample handling.

ADMA won't replace blood pressure measurement or a lipid panel, but it adds a layer about endothelial function that those basics can miss. Trending it alongside kidney function, inflammation, and core cardiometabolic markers over time — quarterly or biannually — lets you see whether changes in training, nutrition, and recovery are moving the underlying biology in a favorable direction.

A comprehensive panel that includes ADMA, SDMA, the L-arginine to ADMA ratio, kidney function, inflammation, and core cardiometabolic markers maps how vascular tone, clearance, and recovery interact in your body. That's the approach behind Superpower and the thinking that drives it — moving beyond population averages toward informed, personalized decisions grounded in evidence and refined with your own trends, in collaboration with a clinician who can put the pieces together.

Join Superpower today to access advanced biomarker testing with over 100 biomarkers.